Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva Plus FOLFOX6 in Advanced Esophageal Cancer
NCT00539617Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Oct 2007
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in esophageal cancer, gastroesophageal junction cancer, sponsored by University of California, San Francisco. Started Oct 2007; status: terminated.
02
Drugs
erlotinib
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00539617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00539617.